Anti-PD-1 therapy may provide a sustained response in patients with PD-L1 expressing angiosarcoma.
May support PD-1 therapy exploration in PD-L1+ angiosarcoma; hypothesis-generating and requires prospective validation.
Although occasional responses to immunotherapy have been reported for sarcomas, this case report demonstrates that angiosarcoma can express PD-L1 and have a sustained response to PD-1 directed therapy.
No takes yet. Share an insight, caveat, or question.
Sindhu et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: